Scholarlink

<p>The field of chimeric antigen receptor (CAR)-T cell therapy is undergoing a paradigm shift from complex ex vivo manufacturing to direct in vivo generation of CAR-T cells. This innovative approach leverages non-viral delivery platforms to reprogram a patient’s own immune cells in situ, promising to overcome critical barriers of cost, scalability, and accessibility. The 2025 American Society of Hematology (ASH) Annual Meeting served as a showcase for groundbreaking preclinical data across a diverse array of non-viral technologies, including advanced lipid nanoparticles (LNPs), virus-like particles (VLPs), and polymeric nanoparticles. This correspondence summarizes the latest reports on these platforms, highlighting their potential to revolutionize the treatment of both autoimmune diseases and hematological malignancies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Bin Xue,
  • Yifan Liu,
  • Aibin Liang,
  • Wenjun Zhang

摘要

The field of chimeric antigen receptor (CAR)-T cell therapy is undergoing a paradigm shift from complex ex vivo manufacturing to direct in vivo generation of CAR-T cells. This innovative approach leverages non-viral delivery platforms to reprogram a patient’s own immune cells in situ, promising to overcome critical barriers of cost, scalability, and accessibility. The 2025 American Society of Hematology (ASH) Annual Meeting served as a showcase for groundbreaking preclinical data across a diverse array of non-viral technologies, including advanced lipid nanoparticles (LNPs), virus-like particles (VLPs), and polymeric nanoparticles. This correspondence summarizes the latest reports on these platforms, highlighting their potential to revolutionize the treatment of both autoimmune diseases and hematological malignancies.